Dr. Hurvitz on Trastuzumab Deruxtecan in Unresectable/Metastatic HER2+ Breast Cancer

Sara A. Hurvitz, MD, associate professor, David Geffen School of Medicine at UCLA; medical director, the Jonsson Comprehensive Cancer Center Clinical Research Unit; co-director, Santa Monica-UCLA Outpatient Oncology Practices; director, Breast Cancer Clinical Trials Program, UCLA, discusses updated survival data with fam-trastuzumab deruxtecan-nxki (Enhertu) in HER2-positive, unresectable/metastatic breast cancer.

The phase 3 DESTINY-Breast03 trial (NCT03529110) investigated trastuzumab deruxtecan vs ado-trastuzumab emtansine (Kadcyla) in patients with HER2-positive, unresectable and/or metastatic breast cancer previously treated with trastuzumab (Herceptin) and a taxane. At the time of data cutoff for an updated survival analysis of this trial, the median overall survival (OS) had not yet been reached for either treatment arm, Hurvitz says. However, the hazard ratio was 0.64, in favor of trastuzumab deruxtecan, and the P value of .0037 was statistically significant, indicating that treatment with trastuzumab deruxtecan prolongs OS in this setting, Hurvitz explains.

Additionally, trastuzumab deruxtecan was associated with a median progression-free survival of 28.8 months vs 6.8 months with trastuzumab emtansine, Hurvitz concludes.